Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efalizumab in Moderate to Severe Chronic Plaque Psoriasis
NCT00249808Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2004
- Primary completion
- Jan 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of efalizumab in plaque psoriasis, sponsored by Merck KGaA. Started Dec 2004; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00249808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00249808.